Alexander Winter

Country flagGermany

Research Interests

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Explore related searches

Articles (9)

Objective To prospectively evaluate functional patient‐reported outcomes (PROs) in patients with low‐risk prostate cancer (PCa) managed with active surveillance (AS), nerve‐sparing radical prostatectomy (NS‐RP), non‐NS‐RP, or radiotherapy (RT). Patients and Methods This multicentre prospective cohort study used data from the Prostate Cancer Outcomes (PCO) study in Germany, Austria and Switzerland, including 6265 patients with low‐risk PCa enrolled between 2016 and 2023. PROs were assessed at baseline and 12 months after treatment/enrolment using the 26‐item Expanded Prostate Cancer Index Composite Short Form (EPIC‐26), measuring urinary continence, bowel, sexual, hormonal, and irritative/obstructive symptoms. Mean score changes were compared with minimal important differences (MIDs) to determine clinical significance. Results In all, 475, 4352, 813, and 625 patients received AS, NS‐RP, non‐NS‐RP, and RT, respectively. At 12 months, AS was associated with stable function across all EPIC‐26 domains. In contrast, both RP groups experienced significant declines in urinary continence (NS‐RP: −18 points; non‐NS‐RP: −26 points) and sexual function (NS‐RP: −35 points; non‐NS‐RP: −30 points), exceeding MID thresholds. Urinary continence did not decline after RT but clinically relevant declines occurred in irritative/obstructive urinary (−5 points), bowel (−7 points), hormonal (−5 points), and sexual function (−12 points). Age‐stratified analysis showed clinically significant declines in urinary and sexual function after NS‐RP across all age groups, with the greatest loss in sexual function among younger patients and the most pronounced continence impairment in the 70–79 years age group. In contrast, functional outcomes under AS remained stable in all age cohorts. Conclusion Active surveillance is underutilised in the observed cohort. Prospective PCO data demonstrates that AS preserves urinary continence and sexual function compared to active treatment, supporting its role as the first‐line strategy for suitable candidates. Despite advancements including NS techniques, RP, and to a lesser extent RT, remain associated with substantial functional impairment even in younger men.

Year:

2026

Purpose Urinary incontinence (UI) is a common condition with significant health and societal implications, particularly among older adults. This study aims to analyze sex-specific differences in associated factors among adults aged 55+. Methods Data from the cross-sectional German Health Update Study (GEDA 2019/2020-EHIS), conducted April 2019 to September 2020, were analyzed for participants aged 55 + years. Differences in UI prevalence by sex were analyzed along possible associated variables (e.g. BMI, education, depressive symptoms (PHQ-8 Score), chronic diseases (any condition expected to last for at least 6 months, self-reported), and limitations of activities of daily living, ADL). UI prevalence was analyzed with 95% confidence intervals (CI). To test for sex differences in associated factors, multivariable logistic regressions were performed. Results Among 12,985 participants, UI prevalence was 14.7% and higher in females (17.8%, 95% CI 16.3–19.4) than males (11.1%, 95% CI 9.8–12.5). Female sex (OR 1.40, 95% CI 1.15–1.70, p < 0.001), age 85 + years (OR 7.07, 95% CI 4.88–10.24, p < 0.001), poor subjective health (OR 1.88, 95% CI 1.50–2.36, p < 0.001), ADL limitations (OR 1.75, 95% CI 1.24–2.48, p = 0.002), and depressive symptoms (OR 2.63, 95% CI 1.84–3.75, p < 0.001) were associated with UI in the multivariable regression. Sex-specific analysis found BMI ≥ 30 (OR 2.07, 95% CI 1.52–2.84, p < 0.001), lower education (OR 1.73, 95% CI 1.27–2.36, p < 0.001) and chronic diseases (OR 1.37, 95% CI 1.01–1.86, p = 0.042) associated with UI only in females. Conclusion The self-reported UI prevalence in the general population is higher among females, but also every 9th male is affected. Due to its prevalence and possible impact on quality of life, attending physicians should have increased awareness of UI among older adults and actively offer treatment options.

Year:

2025

Year:

2024

Purpose: Surveillance of clinical stage I (CSI) testicular germ cell tumors (GCT) is hampered by low sensitivity and specificity of current biomarkers for detecting relapses. This study evaluated if serum levels of microRNA371a-3p (M371 test) can: (i) Accurately detect relapses, (ii) detect relapses earlier than conventional technology, and (iii) if elevated postoperative M371 levels may predict relapse. Experimental Design: In a multicentric setting, 258 patients with testicular CSI GCT were prospectively followed by surveillance for a median time of 18 months with serial measurements of serum M371 levels, in addition to standard diagnostic techniques. Diagnostic characteristics of M371 for detecting relapses were calculated using ROC curve analysis. Results: Thirty-nine patients recurred (15.1%), all with elevated M371 levels; eight without relapse had elevations, too. The test revealed the following characteristics: area under the ROC curve of 0.993, sensitivity 100%, specificity 96.3%, positive predictive value 83%, negative predictive value 100%. Earlier relapse detection with the test was found in 28%, with non-significant median time gain to diagnosis. Postoperative M371 levels did not predict future relapse. Conclusions: The sensitivity and specificity of the M371 test for detecting relapses in CSI GCTs are much superior to those of conventional diagnostics. However, post-orchiectomy M371 levels are not predictive of relapse, and there is no significant earlier relapse detection with the test. In all, there is clear evidence for the utility of the M371 test for relapse detection suggesting it may soon be ready for implementation into routine follow-up schedules for patients with testicular GCT.

Year:

2024

Purpose: Surveillance of clinical stage I (CSI) testicular germ cell tumors (GCT) is hampered by low sensitivity and specificity of current biomarkers for detecting relapses. This study evaluated if serum levels of microRNA371a-3p (M371 test) can: (i) Accurately detect relapses, (ii) detect relapses earlier than conventional technology, and (iii) if elevated postoperative M371 levels may predict relapse. Experimental Design: In a multicentric setting, 258 patients with testicular CSI GCT were prospectively followed by surveillance for a median time of 18 months with serial measurements of serum M371 levels, in addition to standard diagnostic techniques. Diagnostic characteristics of M371 for detecting relapses were calculated using ROC curve analysis. Results: Thirty-nine patients recurred (15.1%), all with elevated M371 levels; eight without relapse had elevations, too. The test revealed the following characteristics: area under the ROC curve of 0.993, sensitivity 100%, specificity 96.3%, positive predictive value 83%, negative predictive value 100%. Earlier relapse detection with the test was found in 28%, with non-significant median time gain to diagnosis. Postoperative M371 levels did not predict future relapse. Conclusions: The sensitivity and specificity of the M371 test for detecting relapses in CSI GCTs are much superior to those of conventional diagnostics. However, post-orchiectomy M371 levels are not predictive of relapse, and there is no significant earlier relapse detection with the test. In all, there is clear evidence for the utility of the M371 test for relapse detection suggesting it may soon be ready for implementation into routine follow-up schedules for patients with testicular GCT.

Year:

2024

In prostate cancer, sentinel lymph node dissection (sLND) offers a personalized procedure with staging ability which is at least equivalent to extended LND while inducing lower morbidity. A bimodal fluorescent–radioactive approach was introduced to improve sentinel LN (SLN) detection. We present the first in-human case series on exploring the use of a fluorescent–magnetic hybrid tracer in a radiation-free sLND procedure. Superparamagnetic iron oxide nanoparticles and indocyanine green were administered simultaneously in five prostate cancer patients scheduled for extended LND, sLND and radical prostatectomy. In situ and ex vivo fluorescence and magnetic signals were documented for each LN sample detected via a laparoscopic fluorescence imaging and magnetometer system. Fluorescence and magnetic activity could be detected in all patients. Overall, 19 lymph node spots could be detected in situ, 14 of which were fluorescently active and 18 of which were magnetically active. In two patients, no fluorescent LNs could be detected in situ. The separation of the LN samples resulted in a total number of 30 SLNs resected. Ex vivo measurements confirmed fluorescence in all but two magnetically active SLNs. One LN detected in situ with both modalities was subsequently shown to contain a metastasis. This study provides the first promising results of a bimodal, radiation-free sLND, combining the advantages of both the magnetic and fluorescence approaches.

Year:

2023

Year:

2023

Year:

2021

Year:

2021

Collaborators (8)

Julia Heinzelbecker

Clinic director

Philipps-Universität Marburg

GERMANY
View details

Luis A. Kluth

-

GERMANY
View details

Axel Heidenreich

-

GERMANY
View details

Peter Törzsök

Paracelsus Medical University

AUSTRIA
View details

Klaus-Peter Dieckmann

Prof

Asklepios Klinik Altona

GERMANY
View details

Martin Pichler

Medical University of Graz

AUSTRIA
View details

Falk Hoffmann

-

GERMANY
View details

Renate Pichler

Medical University of Innsbruck

AUSTRIA
View details